Research Analysts Set Expectations for Krystal Biotech, Inc.’s FY2027 Earnings (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Research analysts at William Blair boosted their FY2027 earnings per share estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, May 22nd. William Blair analyst T. Lugo now expects that the company will post earnings per share of $8.76 for the year, up from their prior estimate of $8.60. William Blair has a “Outperform” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.85) per share.

A number of other analysts have also recently weighed in on the company. HC Wainwright increased their price objective on Krystal Biotech from $119.00 to $139.00 in a research report on Monday. The Goldman Sachs Group raised Krystal Biotech from a “neutral” rating to a “buy” rating and raised their price target for the company from $79.00 to $124.00 in a report on Tuesday, February 28th. Chardan Capital raised their price target on Krystal Biotech from $133.00 to $148.00 in a report on Monday. Guggenheim raised their price target on Krystal Biotech from $101.00 to $130.00 in a report on Monday. Finally, Bank of America raised their price target on Krystal Biotech from $105.00 to $118.00 in a report on Sunday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $126.83.

Krystal Biotech Trading Up 1.4 %

Krystal Biotech stock opened at $119.13 on Tuesday. Krystal Biotech has a twelve month low of $49.17 and a twelve month high of $123.84. The stock has a 50 day moving average of $84.99 and a two-hundred day moving average of $80.50. The stock has a market capitalization of $3.07 billion, a price-to-earnings ratio of -22.56 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last posted its quarterly earnings data on Monday, February 27th. The company reported ($1.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.01.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its position in shares of Krystal Biotech by 14.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,101 shares of the company’s stock valued at $88,000 after purchasing an additional 140 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Krystal Biotech by 1.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 8,485 shares of the company’s stock valued at $672,000 after purchasing an additional 150 shares during the period. Arizona State Retirement System grew its position in shares of Krystal Biotech by 3.0% in the first quarter. Arizona State Retirement System now owns 5,222 shares of the company’s stock valued at $418,000 after purchasing an additional 153 shares during the period. Legal & General Group Plc grew its position in shares of Krystal Biotech by 2.2% in the fourth quarter. Legal & General Group Plc now owns 7,120 shares of the company’s stock valued at $564,000 after purchasing an additional 155 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Krystal Biotech by 3.7% in the third quarter. ProShare Advisors LLC now owns 4,511 shares of the company’s stock valued at $315,000 after purchasing an additional 161 shares during the period. Hedge funds and other institutional investors own 80.80% of the company’s stock.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 28,428 shares of Krystal Biotech stock in a transaction on Friday, May 19th. The stock was sold at an average price of $95.05, for a total transaction of $2,702,081.40. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at $1,193,447.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Krystal Biotech news, CAO Kathryn Romano sold 28,428 shares of the firm’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $95.05, for a total transaction of $2,702,081.40. Following the completion of the transaction, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,193,447.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dino A. Rossi sold 40,000 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $83.25, for a total value of $3,330,000.00. Following the transaction, the director now directly owns 83,691 shares of the company’s stock, valued at approximately $6,967,275.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 193,428 shares of company stock valued at $17,965,513. 17.00% of the stock is owned by insiders.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.